Our top pick for
Beginners
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Atreca stock
Own Atreca stock in just a few minutes.
Atreca, Inc is a biotechnology business based in the US. Atreca shares (BCEL) are listed on the NASDAQ and all prices are listed in US Dollars. Atreca employs 130 staff and has a market cap (total outstanding shares value) of USD$641.6 million.
How to buy shares in Atreca
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Atreca. Find the stock by name or ticker symbol: BCEL. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Atreca reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Atreca, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Atreca. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Atreca share price
Use our graph to track the performance of BCEL stocks over time.Atreca shares at a glance
Information last updated 2021-03-03.
| 52-week range | USD$10.8807 - USD$27.89 |
|---|---|
| 50-day moving average | USD$16.3781 |
| 200-day moving average | USD$15.0669 |
| Wall St. target price | USD$30 |
| PE ratio | 4.4373 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-18.879 |
Buy Atreca shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Atreca stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Atreca under- or over-valued?
Valuing Atreca stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Atreca's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Atreca's P/E ratio
Atreca's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Atreca shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Atreca financials
| Gross profit TTM | USD$0 |
|---|---|
| Return on assets TTM | -23.75% |
| Return on equity TTM | -40.25% |
| Profit margin | 0% |
| Book value | $7.332 |
| Market capitalisation | USD$641.6 million |
TTM: trailing 12 months
Shorting Atreca shares
There are currently 3.4 million Atreca shares held short by investors – that's known as Atreca's "short interest". This figure is 7.4% up from 3.2 million last month.
There are a few different ways that this level of interest in shorting Atreca shares can be evaluated.
Atreca's "short interest ratio" (SIR)
Atreca's "short interest ratio" (SIR) is the quantity of Atreca shares currently shorted divided by the average quantity of Atreca shares traded daily (recently around 287313.64016736). Atreca's SIR currently stands at 11.95. In other words for every 100,000 Atreca shares traded daily on the market, roughly 11950 shares are currently held short.
However Atreca's short interest can also be evaluated against the total number of Atreca shares, or, against the total number of tradable Atreca shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atreca's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Atreca shares in existence, roughly 90 shares are currently held short) or 0.156% of the tradable shares (for every 100,000 tradable Atreca shares, roughly 156 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Atreca.
Find out more about how you can short Atreca stock.
Atreca share dividends
We're not expecting Atreca to pay a dividend over the next 12 months.
Atreca overview
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a strategic research collaboration with Merck Sharp & Dohme Corp. to identify the antigenic targets of select antibodies discovered with potential utility in oncology. Atreca, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Frequently asked questions
More guides on Finder
-
How to buy Reddit (BCEL.US) stock when it goes public
Everything we know about the Reddit IPO, plus information on how to buy in.
-
How to buy Hayward Holdings Inc (HAYW) stock when it goes public
Everything we know about the Hayward Holdings Inc IPO, plus information on how to buy in.
-
How to buy Alignment Healthcare Inc (ALHC) stock when it goes public
Everything we know about the Alignment Healthcare Inc IPO, plus information on how to buy in.
-
How to buy Olink Holding AB (publ) (OLK) stock when it goes public
Everything we know about the Olink Holding AB (publ) IPO, plus information on how to buy in.
-
How to buy Procore (PCOR) stock when it goes public
Everything we know about the Procore IPO, plus information on how to buy in.
-
How to buy Navios South American Logistics Inc (NSAL) stock when it goes public
Everything we know about the Navios South American Logistics Inc IPO, plus information on how to buy in.
-
How to buy Lava Therapeutics (LVRX) stock when it goes public
Everything we know about the Lava Therapeutics IPO, plus information on how to buy in.
-
How to buy Pop Culture Group Co Ltd (CPOP) stock when it goes public
Everything we know about the Pop Culture Group Co Ltd IPO, plus information on how to buy in.
-
How to buy Bukalapak (BCEL.US) stock when it goes public
Everything we know about the Bukalapak IPO, plus information on how to buy in.
-
How to buy Achilles Therapeutics plc (ACHL) stock when it goes public
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Ask an Expert